Punjab Chemicals & Crop Protection Ltd Q2 FY26 | ₹255 Cr Revenue, ₹18.5 Cr PAT, 50% Profit Jump — The Quiet Chemist Cooking Big Contracts in Silence
1. At a Glance
Punjab Chemicals & Crop Protection Ltd (PCCPL) is that silent performer in the Indian chemicals space — no fancy influencer CEO, no 100x hype on X, just old-school chemistry quietly compounding returns. The Q2 FY26 numbers? A classic “don’t shout, just show” quarter.
Revenue stood at ₹255 crore, up 5.4% YoY, while profit after tax jumped nearly 50% YoY to ₹18.5 crore. Operating margin was a modest 10%, but stable amid industry volatility. The stock trades around ₹1,347, giving it a market cap of ₹1,645 crore, with a P/E of 30x — expensive for a fertilizer company, but reasonable for a niche chemical manufacturer with export muscle.
Over the last six months, the stock’s up 26.8%. Over five years — up 17%. The journey’s not flashy but remarkably steady, like an IIT topper who became a solid scientist instead of a crypto trader. With ROE at 12%, ROCE at 15.3%, and debt down to ₹168 crore, this is not a leverage party — it’s a lab experiment running safely within limits.
2. Introduction
What if I told you Punjab Chemicals isn’t really “Punjab” anymore — it’s global? From supplying BASF and Bayer to Coke and Pepsi, this 50-year-old chemical craftsman quietly exports 39% of its production to Europe, Japan, and Latin America. It’s the kind of company you discover while researching UPL, then realize, “Oh wait, these guys actually make the intermediates everyone else uses.”
The story started in 1975, when most of us weren’t even molecules yet. Fast-forward to FY25, PCCPL is a full-spectrum player in Agrochemicals, Pharma Intermediates, and Industrial Chemicals. It also does CRAMS (Contract Research and Manufacturing Services) — the fancy term for “we make complex stuff that other companies can’t, and we don’t brag about it.”
This quarter’s 50% PAT jump wasn’t luck. It’s the result of stable capacity utilization (71% at Derabassi, 64% at Lalru), disciplined working capital, and strong demand from global clients. Sure, debtor days have stretched from 74 to 95, but when your top 5 customers are Bayer, Corteva, and PepsiCo, you can afford to wait a bit.
The market’s ignoring PCCPL because it’s not loud. But beneath the surface — there’s chemistry worth noticing.
3. Business Model – WTF Do They Even Do?
Punjab Chemicals operates in three interconnected verticals:
Agrochemicals & Intermediates: This is the bread and butter — herbicides, fungicides, insecticides, and agro intermediates. The company specializes in complex chemistries like chlorination, bromination, methylation, and heterocyclic reactions — the kind of stuff that makes your college lab assistant faint.
Performance & Specialty Chemicals: The real margin drivers. PCCPL makes intermediates for APIs and performance materials through deep chemistries like halogenation, esterification, and pyrazole reactions. In simple terms — they make the ingredients for other high-margin products, and get paid to stay invisible.
Industrial Chemicals: Focused on high-purity phosphorous-based compounds. Used in everything from flame retardants to water treatment. Not sexy, but recurring.
Add to that a CRAMS business, where they manufacture patented molecules for global innovators under long-term agreements. In short — PCCPL is not selling final products to farmers or patients; it’s selling to companies that sell to them.
And unlike your typical “chemical story,” it doesn’t rely on a single molecule or geography. 61% domestic, 39% export — balanced like a perfect titration.
4. Financials Overview
Consolidated (₹ crore)
Source table
Metric
Latest Qtr (Sep’25)
YoY Qtr (Sep’24)
Prev Qtr (Jun’25)
YoY %
QoQ %
Revenue
255
242
320
5.4%
-20.3%
EBITDA
26
26
34
0%
-23.5%
PAT
18.5
12.3
21.0
49.9%
-11.9%
EPS (₹)
15.1
10.1
16.8
49.5%
-10.1%
Commentary: YoY profit almost doubled, but QoQ slowdown shows a normal post-season slump after a heavy Q1. EBITDA margins stable near 10–11%, which is decent in a world where bromine prices fluctuate like Bitcoin.
Annualized EPS = ₹15.1 × 4 = ₹60.4 ⇒ Implied P/E ~22x — much lower than the reported 30x because H1 was strong. That’s the sign of underappreciation, not overvaluation.
5. Valuation Discussion – Fair Value Range Only
Let’s decode this like a lab formula.
a) P/E Approach TTM EPS = ₹42.6 Industry P/E ≈ 31x
→ Fair Value Range = ₹42.6 × (25x–35x) = ₹1,065 – ₹1,490 per share
b) EV/EBITDA Approach EV = ₹1,795 crore TTM EBITDA = ₹105 crore ⇒ EV/EBITDA = 17.1x Peers (Dhanuka, Sharda, PI) average around 15x–20x
→ Fair EV range = 15x–18x EBITDA ⇒ ₹1,575 – ₹1,890 crore EV ⇒ Per Share ₹1,200 – ₹1,440
c) DCF (Simplified) Assume FCF growth 8%, discount 10%, terminal 3%, base FCF ₹30 crore. DCF
